TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer
- Author(s)
- Agarwal, N; Saad, F; Azad, AA; Mateo, J; Matsubara, N; Shore, ND; Chakrabarti, J; Chen, HC; Lanzalone, S; Niyazov, A; Fizazi, K;
- Details
- Publication Year 2024-03,Volume 20,Issue #9,Page 493-505
- Journal Title
- Future Oncology
- Publication Type
- Protocol
- Abstract
- Poly(ADP-ribose) polymerase inhibitors in combination with androgen-receptor signaling inhibitors are a promising therapeutic option for patients with metastatic castration-sensitive prostate cancer (mCSPC) and homologous recombination repair (HRR) gene alterations. Here, we describe the design and rationale of the multinational, phase III, TALAPRO-3 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide in patients with mCSPC and HRR gene alterations. The primary end point is investigator-assessed radiographic progression-free survival (rPFS) per RECIST 1.1 in soft tissue, or per PCWG3 criteria in bone. The TALAPRO-3 study will demonstrate whether the addition of talazoparib can improve the efficacy of enzalutamide as assessed by rPFS in patients with mCSPC and HRR gene alterations undergoing androgen deprivation therapy. Clinical Trial Registration:NCT04821622 (ClinicalTrials.gov) Registry Name: Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC. Date of Registration: 29 March 2021.
- Publisher
- Future Medicine
- Keywords
- Male; Humans; *Prostatic Neoplasms, Castration-Resistant/drug therapy/genetics; Androgen Antagonists/therapeutic use; Androgens; Nitriles/therapeutic use; Castration; Clinical Trials, Phase III as Topic; *Benzamides; *Phenylthiohydantoin; *Phthalazines; Hrr; PARP inhibitor; androgen receptor; enzalutamide; mCSPC; talazoparib
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.2217/fon-2023-0526
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-03-28 06:51:20
Last Modified: 2024-03-28 06:51:29